chr17:37868196:> Detail (hg19) (ERBB2)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr17:37,868,196-37,881,332 |
| hg38 | chr17:39,711,943-39,725,079 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| bladder carcinoma | Platinum Compound | C |
|
|
Sensitivity/Response | Somatic | 3 | 25636205 | Detail |
| breast cancer | Neratinib | B |
|
|
Sensitivity/Response | Somatic | 4 | 28679771 | Detail |
| lung non-small cell carcinoma | Pertuzumab,Trastuzumab | B |
|
|
Sensitivity/Response | Somatic | 2 | 29320312 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemot... | CIViC Evidence | Detail |
| 16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of t... | CIViC Evidence | Detail |
| The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- Genome
- hg19
- Position
- chr17:37,868,196-37,881,332
- Variant Type
- snv
- Variant (CIViC) (CIViC Variant)
- MUTATION
- Transcript 1 (CIViC Variant)
- ENST00000269571.5
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/666
Genome browser